This study is testing a new diagnostic tool called Seravue for detecting liver cancer (Hepatocellular Carcinoma or HCC). Currently, ultrasound and a blood test called AFP are used, but they aren't always accurate enough, especially in early stages. Researchers want to see if Seravue, either alone or with ultrasound, can better identify HCC in people aged 21 to 84. The study will compare Seravue's performance against current methods over 24 months. This is an observational study, meaning you won't receive a new treatment, but your health will be monitored to see how well Seravue works.

Study design

This is an observational study planning to enroll 1392 participants. It will compare the Seravue device to standard methods for detecting liver cancer.

What's involved

You would have baseline assessments and blood draws, plus hepatic ultrasound and AFP testing at enrollment, 6, 12, and 18 months, or until HCC diagnosis. Your medical records will be reviewed at 24 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 24 months from enrollment, or until an HCC diagnosis is confirmed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.